ALTA Drug Series
Alzheimer's Disease
Key Facts
About Alteron Therapeutics
Alteron Therapeutics is a private, preclinical-stage biotechnology company focused on discovering and developing precision therapies targeting TDP-43 proteinopathy, a root cause of several neurodegenerative diseases including ALS, Alzheimer's disease, and frontotemporal lobar degeneration (FTLD), as well as cystic fibrosis. The company's core innovation is the ALTA series of small molecule drugs designed to inhibit TDP-43's toxic nucleic acid binding by targeting its guanine pocket. Founded in the late 2010s and incubated at Western Michigan University, Alteron is advancing its lead candidate, ALTA-808, towards IND-enabling studies with the goal of rapidly reversing symptoms in debilitating conditions.
View full company profileAbout Alteron Therapeutics
Alteron Therapeutics is a private, preclinical-stage biotechnology company focused on discovering and developing precision therapies targeting TDP-43 proteinopathy, a root cause of several neurodegenerative diseases including ALS, Alzheimer's disease, and frontotemporal lobar degeneration (FTLD), as well as cystic fibrosis. The company's core innovation is the ALTA series of small molecule drugs designed to inhibit TDP-43's toxic nucleic acid binding by targeting its guanine pocket. Founded in the late 2010s and incubated at Western Michigan University, Alteron is advancing its lead candidate, ALTA-808, towards IND-enabling studies with the goal of rapidly reversing symptoms in debilitating conditions.
View full company profileAbout Alteron Therapeutics
Alteron Therapeutics is a private, preclinical-stage biotechnology company focused on discovering and developing precision therapies targeting TDP-43 proteinopathy, a root cause of several neurodegenerative diseases including ALS, Alzheimer's disease, and frontotemporal lobar degeneration (FTLD), as well as cystic fibrosis. The company's core innovation is the ALTA series of small molecule drugs designed to inhibit TDP-43's toxic nucleic acid binding by targeting its guanine pocket. Founded in the late 2010s and incubated at Western Michigan University, Alteron is advancing its lead candidate, ALTA-808, towards IND-enabling studies with the goal of rapidly reversing symptoms in debilitating conditions.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |